China Resources Double-Crane released its 2026 interim report on August 22, 2026. Net profit attributable to the parent company was 946 million yuan, down 3.43% from the same period last year. Total operating revenue was 5.615 billion yuan, down 3.44% year-on-year. Net cash inflow from operating activities was 621 million yuan, down 8.18% year-on-year. The company's latest asset-liability ratio was 28.45%, gross margin was 58.11%, ROE was 7.73%, and diluted earnings per share was 0.92 yuan.
China Resources Double-Crane Pharmaceutical Co LtdNet profit and revenue declined year-on-year
Beijing Winsunny Pharmaceutical CO.LTD